Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in
subjects with moderate to severe plaque psoriasis. It is designed to evaluate the effect of
brodalumab on midazolam PK in addition to assessing single dose PK of brodalumab in subjects
with moderate to severe plaque psoriasis.